Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
80407.010.7094%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Quince Therapeutics Inc

QNCXNASDAQ
Trade with Public
Trade with Public
$31.32
0.772.52%
At close: Sep 4, 5:00 PM EST
$31.00
-0.32-1.02%
After Hours: Sep 4, 5:22 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Quince Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Quince Therapeutics (QNCX).

Price Target Range — 8 Quarters

Analyst Consensus — 10 Analysts

1S.Buy
7Buy
2Hold
Consensus RatingBuy# Analysts10Avg. Consensus PT$24Upside to Avg. PT-24.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 18, 2026Cantor FitzgeraldOlivia Brayer SaundersMaintainedOverweight$70
Jul 29, 2026OppenheimerMazahir AlimohamedInitiateOutperform$82
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Cantor Fitzgerald Reiterates Overweight on Quince Therapeutics, Maintains $70 Price Target

Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Quince Therapeutics (NASDAQ:QNCX) with a Overweight and maintains $70 price target.
Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $82

Oppenheimer analyst Mazahir Alimohamed initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Outperform rating and announces Price Target of $82.
Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $4

Leerink Partners analyst Joseph Schwartz initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Outperform rating and announces Price Target of $4.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Quince Therapeutics with Overweight Rating, Announces Price Target of $4

Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Quince Therapeutics (NASDAQ:QNCX) with a Overweight rating and announces Price Target of $4.
Benzinga Newsdesk

This Codere Online Luxembourg Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday

Avi Kapoor

PRO
Citizens Downgrades Quince Therapeutics to Market Perform

Citizens analyst Jonathan Wolleben downgrades Quince Therapeutics (NASDAQ:QNCX) from Market Outperform to Market Perform.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved